CBPartners Leads Session on AMNOG during Full-Day Symposium on Value-Based Pricing in Istanbul, Turkey

Share Article

The session took place in May 2013 and focused on: elucidating Germany’s new early benefit assessment system created through AMNOG and discussing its application to the Turkish environment.

CBPartners, a global leader in pricing, market access, and health economics / value demonstration, led a working session with the Turkish Ministry of Health in late May, which focused on discussing how pharmacoeconomics and value-based-pricing can be incorporated within Turkey’s healthcare system.

The symposium, entitled Value-Based Pricing in Health Care: Equal Impact, Equal Reimbursement? took place in Istanbul, Turkey on May 10, 2013. Organised by the Health Economics & Policy Association in Turkey, the day included several thought leaders on HTA in Turkey, including Dr. Hakkı Gürsöz, Deputy Director at the Turkish Medicines and Medical Devices Agency, and Dr. Ufuk Akdıkan, General Directorate of the Social Security Institution for General Health Insurance. The session on the application of Germany’s AMNOG system was led by Mr. Cyrus A. Chowdhury, Chief Executive Officer of CBPartners.

“Turkish officials have requested pharmacoeconomic data as a part of new product reimbursement dossiers since 2009, but a formal system for evaluating the clinical or cost benefit of a new therapy has yet to take shape,” explains Mr. Chowdhury. “Turkey has long been among the more progressive emerging markets, and the world is waiting to see how Turkey’s actions on this topic will ensue, and whether they can be applied to other emerging markets.”

Mr. Chowdhury continues, “Germany’s early-benefit assessment system developed through the AMNOG legislation is quickly becoming a high profile blueprint for many other governments evaluating how to incorporate HTA within their health care systems. We would be quick to caution, however, that the German system is not without controversy and also takes advantage of the local environment, which includes a strong pharmacoeconomic resource pool within local acadaemia, and a robust domestic pharmaceutical industry lobby. In other words, Germany has been able to successfully implement its new system through the support of its environment, not just its legislation.”

CBPartners continues to lead the world in thought leadership on value-based pricing and HTA through its Government Policy Advisory practice that works with both governments and government affairs executives within pharmaceutical and biopharmaceutical companies.

For more information about the session or conference, please visit http://www.cbpartners.com.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical / pharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout over 70 countries. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Cyrus Chowdhury
CB Partners
+1 347 221 9536
Email >
Follow us on
Visit website